SCHEMBL2397571

SCHEMBL2397571

O=CC(F)(F)c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 5/20 0.43
CYP1A1 P04798 1/20 0.39
CYP1B1 Q16678 1/20 0.39
HSD11B1 P28845 2/20 0.37
RAB9A P51151 2/20 0.37
USP2 O75604 1/20 0.37
MAOB P27338 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
XBP1 P17861 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CES2 O00748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2007205 0.79 ALDH1A1 (0.50) KCNN4CYP1A1CYP1B1RAB9AMAOB
SCHEMBL16147297 0.77 CA2 (0.48) CYP1A1CYP1B1RAB9AMEN1NPC1
SCHEMBL8581116 0.77 HSD17B10 (0.44) MEN1MAPK1KMT2ACYP19A1
SCHEMBL11431 0.77 CA2 (0.48) MAPK1CES2CES1CYP19A1CA1
SCHEMBL3823650 0.75 NPC1 (0.45) MAOBNPC1
SCHEMBL3364629 0.74 KCNN4 (0.43) KCNN4CYP1A1CYP1B1HSD11B1RAB9A
SCHEMBL23176905 0.73 ACHE (0.35) KCNN4CYP1A1CYP1B1HSD11B1RAB9A
SCHEMBL15094384 0.73 KCNN4 (0.42) KCNN4RAB9ACYP2D6CYP2C9MEN1
SCHEMBL17996517 0.72 KCNN4 (0.46) KCNN4CYP1A1CYP1B1HSD11B1RAB9A
SCHEMBL7929127 0.72 ESR1 (0.59) KCNN4CYP1A1CYP1B1HSD11B1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425505-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-12-26 US disclosed
US-12110290-B2 Triazolopyridinyl compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-10-08 US disclosed
EP-4364737-A2 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2024-05-08 EP disclosed
EP-4229056-B1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-04-10 EP disclosed
US-20240109888-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-04-04 US disclosed
US-11767322-B2 Triazolopyridinyl compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-09-26 US disclosed
CN-116802181-A Triazolopyridine compounds as kinase inhibitors 百时美施贵宝公司 2023-09-22 CN disclosed
EP-4229056-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2023-08-23 EP disclosed
WO-2022086828-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2022-04-28 WO disclosed
US-20220119388-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2022-04-21 US disclosed
US-8013186-B2 Haloalkyl containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2011-09-06 US disclosed
US-20090023781-A1 Haloalkyl Containing Compounds as Cysteine Protease Inhibitors VIROBAY, INC. (US) 2009-01-22 US disclosed
EP-1817275-A1 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS Schering Aktiengesellschaft (DE) 2007-08-15 EP disclosed
WO-2006060494-A1 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119388-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS RIPK1, RIPK3, RIPK4 KCNN4 3343/4885CYP1A1 2738/4885CYP1B1 2707/4885
US-20090023781-A1 Haloalkyl Containing Compounds as Cysteine Protease Inhibitors CTSF, CTSS, CTSE KCNN4 3890/4885CYP1A1 3294/4885CYP1B1 1908/4885
US-20240109888-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS RIPK1, RIPK3, RIPK4 KCNN4 3343/4885CYP1A1 2738/4885CYP1B1 2707/4885
US-11767322-B2 Triazolopyridinyl compounds as kinase inhibitors RIPK1, RIPK3, RIPK4 KCNN4 3343/4885CYP1A1 2738/4885CYP1B1 2707/4885
US-12110290-B2 Triazolopyridinyl compounds as kinase inhibitors RIPK1, RIPK3, RIPK4 KCNN4 3343/4885CYP1A1 2738/4885CYP1B1 2707/4885
US-20240425505-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS RIPK1, RIPK3, RIPK4 KCNN4 3343/4885CYP1A1 2738/4885CYP1B1 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.